Introduction
Sjögren's syndrome (SS) is a systemic autoimmune condition with an average annual incidence of 4-6 per 100,000 population [ 1 ]. It occurs mainly among women within the fourth and sixth decades of life. SS manifests with a spectrum varying from mild sicca and dry mouth, characterized by mucosal dryness following exocrine glands infiltration by lymphocytes accompanied by B-cells activation, to severe systemic involvement [ 1 - 3 ].
In patients with SS, studies have illustrated a higher incidence of non-Hodgkin’s lymphoma (NHL) compared to the general population, but little is known about the risk of developing other cancer types, including solid tumors [ 4 , 5 ].
This rare case report describes a 60-year-old woman with a history of SS who presented with abdominal distension, found to have ascites from peritoneal carcinomatosis, and eventually diagnosed with poorly differentiated gastric adenocarcinoma.
Case presentation
A 60-year-old woman with a past medical history pertinent for hypothyroidism and SS presented to the ED complaining of worsening abdominal distention that started six weeks prior. Of note, the patient was evaluated and treated in the past several months with a proton pump inhibitor (PPI), omeprazole, for suspected gastritis by her primary care physician (PCP). The patient, however, was having persistent symptoms despite the treatment and was sent to a gastrointestinal (GI) physician for further evaluation. Unfortunately, she was unable to see a GI physician for several months and could not take the discomfort any longer, and thus, her PCP sent her to the ED. Upon her ED presentation, she relates that her condition was associated with fatigue, nausea, anorexia, and denied any fever, chills, night sweats, change in weight, or bowel habits. She reports only taking levothyroxine and occasional diclofenac sodium. She denied any family history of cancers. She had an unremarkable screening mammogram and pap smear that was done 12 months ago. She denied any herbal medication use, exposure to chemicals, tobacco, alcohol, or illicit drug use.
The physical examination was pertinent for a distended, non-tender abdomen. Laboratory workup was relevant for white blood cell (WBC) of 6.2 x 10 3 /µL, hemoglobin of 11/8 g/dL, platelet count of 300 K/µL, sodium of 140 mmol/L, potassium of 4 mmol/L, creatinine of 0.9 mg/dL, lactic acid of 1.2 mmol/L, prothrombin time of 11.2 seconds, and an INR of 1.1. CT scan of the chest showed 6 mm left upper lobe and 1 cm right middle lobe pulmonary nodules (Figure 1 ). CT scan of the abdomen and pelvis revealed a large amount of ascitic fluid, with diffuse omental thickening, extensive mesenteric, and retroperitoneal lymphadenopathy (Figure 2 ). These findings suggested a neoplastic process secondary to peritoneal carcinomatosis.
Thereafter, the patient had a diagnostic and therapeutic paracentesis. The ascitic fluid SAAG was 1.1, and cytologic examination revealed numerous metastatic cells positive for CK19, CK20, BerEP4, CEA, and MOC-31. Rare cells were positive for CK7 and HBME-1 and were negative for mucicarmine, calretinin, WT-1, ER, mammaglobin, TTF-1, caldesmon, D2-40, and PAX-8. There was no definitive staining for CA-125 (Figure 3A -R). These findings were consistent with poorly differentiated carcinoma of unknown primary. Further testing revealed CA125 was elevated at 434 U/mL.
Given that the ovaries were small with no apparent masses, and the uterus was normal-appearing, therefore, the radiologists were asked to review the CT scan images where they noticed that the stomach wall appeared to be abnormally thickened, even despite being under-filled (Figure 4 ). Therefore, the gastric source of her cancer was placed higher on the differential, especially with her upper GI symptoms that were not responsive to PPI therapy. GI physician evaluated the patient, and thus, endoscopy with esophagogastroduodenoscopy (EGD) and colonoscopy was then advised as the gastric malignancy was in the differential. EGD showed a circumferential malignant appearing mass lesion in the gastric fundus, which was biopsied, and colon was unremarkable. Pathology revealed poorly differentiated adenocarcinoma with surface ulceration of the gastric fundus, and the patient was diagnosed with stage IV gastric adenocarcinoma.
The patient was later discharged from the hospital and referred to the oncology clinic. The patient was offered palliative chemotherapy with IV cisplatin and oral capecitabine. However, she can't swallow pills, and thus, she was offered the option of carboplatin with paclitaxel, or carboplatin with 5-FU (fluorouracil) but the patient felt that she was too weak and fatigued to tolerate the therapy and thus, she elected to not pursue palliative chemotherapy and desired hospice therapy for comfort care. The patient died two months after her initial diagnosis.
Discussion
Globally, gastric carcinoma endures one of the most common cancers, with approximately 27,510 patients are diagnosed annually in the United States, of whom 11,140 are expected to die [ 6 ]. Gastric adenocarcinoma is the most common type of primary gastric carcinoma and accounts for 95% of cases, followed by primary gastric lymphoma [ 7 ].
Malignancy was reported as the leading cause of death in patients with SS [ 8 ]. The relation of autoimmune diseases with increased risk of malignancy has been well established. In particular, the increased risk of NHL in SS patients is widely recognized, though the uncertainty regarding the risk of cancers other than NHL in these patients remains obscure [ 4 , 5 , 9 ]. Extra-nodal sites of involvement by NHL could also be present, with the stomach being seldom reported in the literature [ 10 ]. Moreover, the SS association with an increased incidence of lymphoma, multiple myeloma, breast, and thyroid carcinoma with respect to the normal population was reported in the literature [ 1 , 11 ].
Zhang et al. reported 29 patients (2.2%) to develop malignancies out of 1,320 patients with SS upon follow-up. Out of those 29 patients, 19 patients (65.5%) developed solid malignancies, and only two patients (6.9%) developed gastric adenocarcinoma [ 12 ]. Therefore, making our patient the third published case that addresses the association between gastric adenocarcinoma in patients with SS and the first published case report detailing the patient’s clinical course, management, and outcome.
This report details the unique presentation of gastric adenocarcinoma. Our patient had non-specific GI symptoms that were not responsive to PPI therapy for several months before presenting with malignant ascites. In our patient, a meticulous search for clues for the primary location of the tumor through evaluating the patient’s history combined with simultaneously re-evaluating the CT scan images from prior studies guided the diagnosis of gastric adenocarcinoma. This diagnosis was established with histologic evidence through endoscopic tissue biopsy.
Conclusions
This article verifies the association between SS and gastric adenocarcinoma and highlights the importance of early diagnosis as delay in diagnosis leads to poor outcomes. The rare association of SS with metastatic gastric carcinoma should be in the differential for patients with SS who presents with GI symptoms and failed initial conservative therapy. Further studies are required to determine the true incidence and convey clinical expertise in establishing guidelines for solid tumors in patients with autoimmune disorders, which could, therefore, aid in improving outcomes.
The authors have declared that no competing interests exist.
Human Ethics
Consent was obtained by all participants in this study
References
1 Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren's syndrome in Taiwan Ann Rheum Dis Weng MY Huang YT Liu MF Lu TH 524 527 71 2012 22072014 10.1136/annrheumdis-2011-200402
2 Primary Sjogren syndrome BMJ Ramos-Casals M Brito-Zerón P Sisó-Almirall A Bosch X 0 344 2012 10.1136/bmj.e3821 22700787
3 Unusual cancer in primary Sjögren syndrome Can Fam Physician Lai WS Liu FC Wang CH Chen HC 912 915 60 2014 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196815/ 25316745 PMC4196815
4 Characterization and risk estimate of cancer in patients with primary Sjögren syndrome J Hematol Oncol Brito-Zerón P Kostov B Fraile G 90 10 2017 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392920/ 28416003 10.1186/s13045-017-0464-5 PMC5392920
5 Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies Int J Cancer Anderson LA Gadalla S Morton LM 398 405 125 2009 19365835 10.1002/ijc.24287 PMC2692814
6 Cancer statistics, 2019 CA Cancer J Clin Siegel RL Miller KD Jemal A 7 34 69 2019 30620402 10.3322/caac.21551
7 Epidemiology of gastric cancer: global trends, risk factors and prevention Prz Gastroenterol Rawla P Barsouk A 26 38 14 2019 30944675 10.5114/pg.2018.80001 PMC6444111
8 Sjögren syndrome, cancer incidence and mortality in Vigo area Ann Rheum Dis Lorenzo R Argibay A Sousa A 1076 1077 75 2016
9 Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis Ann Rheum Dis Liang Y Yang Z Qin B Zhong R 1151 1156 73 2014 23687261 10.1136/annrheumdis-2013-203305
10 Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome Arthritis Rheum Voulgarelis M Dafni UG Isenberg DA Moutsopoulos HM 1765 1772 42 1999 10446879 10.1002/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V
11 Adenocarcinoma of the lung and Sjogren's syndrome: an unlikely pair Am J Respir Crit Care Med Brown A Luckhardt TR 0 189 2014 https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A6072
12 Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort Rheumatology (Oxford) Zhang W Feng S Yan S 571 577 49 2010 20040528 10.1093/rheumatology/kep404